Accendra Health, Inc. (ACH)

From the record

Accendra Health, Inc.'s filings since 2017 show 4 warning events of 3 kinds: a debt default or acceleration notice (8-K item 2.04, the latest 2025-06-06); a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2026-10-30); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2019-03-04) (its current reports).

From the record

Accendra Health, Inc.'s 10 filed years say what it did: revenue went from $9.7 billion in fiscal 2016 to $2.8 billion in fiscal 2025, down 13.1% a year; it rose in 5 of 9 years; the deepest fall was 74% from fiscal 2022 to fiscal 2023; net income was positive in 5 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Accendra Health, Inc.'s diluted share count grew about 0.3% a year, and dividends and buybacks returned about 1% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-10-06 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Accendra Health, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 53 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 119 cents per dollar of assets, and net share issuance: its share count grew 0.2% over the year (the filed statements).

From the record

Accendra Health, Inc.'s standing among 51 graded names in its industry family: revenue of $2.8 billion in fiscal 2025 ranks in the top 48% by size; a net margin of -39.8% ranks in the bottom 17%; revenue growth of -34.8% a year over the last 3 filed years ranks in the bottom 11% (its annual reports).

From the record

Accendra Health, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Gardner-Smith, Kenneth (President & CEO, as filed), filing under that title since 2026-10-06, 1 month (bottom 3% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 6.2 years (bottom 47%); 18 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 4%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Accendra Health, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $282 million against debt of $1.8 billion leaves -61.9% of its assets as net cash, bottom 3% of its family; cash from operations less capital spending is -10.6% of revenue (bottom 19%); a gross margin of 46.7% (top 3%) (its annual report).

From the record

Accendra Health, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -34.8% a year over the last three filed years against -13.1% over all 10, slowing (bottom 9% of its family); the newest year grew 3.1% (bottom 41%); research spending grew 2.4% a year (bottom 36%); capital spending grew 6.5% a year (top 47%) (its annual reports). Accendra Health, Inc. reported 7 product lines in fiscal 2025: Diabetes Product at $783 million (28%), Sleep Therapy Product at $740 million (27%), Home Respiratory Therapy Product at $433 million (16%), and 4 more; 5 of 7 grew against the year before (its annual report).

From the record

Accendra Health, Inc.'s newest year against its own record: revenue of $2.8 billion in fiscal 2025 came in 98.5% above the $1.4 billion its prior three years' pace pointed to (top 8% of its family); net income of $1.1 billion against a prior three-year average of $127 million (bottom 3%); a net margin of -39.8% against -5% before (bottom 13%) (its annual reports).